The U.S. Food and Drug Administration has issued an approval (status AP) for application ANDA078441 submitted by IMPAX LABS. The approval covers oral tablet products of the active ingredient ACARBOSE, marketed as prescription drugs.
Three dosage strengths are approved: 25 mg, 50 mg, and 100 mg tablets. All products are designated as non‑reference (generic) drugs and are intended for oral administration.
규제 업데이트2026년 9월 9일•3분 읽기
FDA Approves IMPAX Labs' ACARBOSE Oral Tablets (ANDA 078441)
FDA granted approval for IMPAX Labs' ANDA 078441, authorizing prescription oral tablets of ACARBOSE in 25 mg, 50 mg, and 100 mg strengths.
Pharmacountry 팀이 정리했습니다 · 출처: FDA.gov
주제:
평점
(0)
(0)
(0)
(0)
(0)
평가 남기기